Anthera Pharmaceuticals, Inc. (ANTH)

[10452km2]

CEO knows how to get things done. Hopefully we see a buyout with this play.


Mr. Truex has served as Director, President and Chief Executive Officer since the inception of Anthera in 2004. He was responsible for negotiating both of Anthera's product licenses for Varespladib, our sPLA2 inhibitor from Eli Lilly, and A-623 our anti-BAFF peptibody program from Amgen. Prior to founding Anthera Pharmaceuticals, Mr. Truex served as a Founder, Director, President and CEO of Peninsula Pharmaceuticals. During that time Mr. Truex raised over $81 million of institutional capital (including $21 million from a strategic partner) and negotiated both of Peninsula's product agreements with Shionogi & Co., Ltd. (Doribax®, doripenem) and Takeda Chemical Industries (Teflaro®, ceftaroline). Peninsula was acquired by Johnson and Johnson in April of 2005 for $245 million in an all cash transaction. The remaining entity, Cerexa was subsequently acquired in 2006 for $480 million in cash. During his career, Mr. Truex has successfully raised over $150 million in venture investments and more than $200 million in various public equity and debt offerings including Anthera's Initial Public Offering in 2010 and Versicor's IPO in 2000. Mr. Truex has extensive experience in sales' marketing and business development in several industries including pharmaceuticals, biotechnology, consumer electronics, and telecommunications. Prior to Peninsula, Mr. Truex was Vice President of Commercial Development for Versicor Incorporated (acquired by Pfizer) where he directed early commercial efforts for their infectious disease portfolio and participated in the company's successful $55 million initial public offering. Prior to joining Versicor, Mr. Truex worked at Eli Lilly and Company where he served in various marketing and sales roles during the launch of three different products for the primary care physician market (Actos®' Evista®' and Humalog 75/25®). His business development experience includes the Lilly ICOS LLC joint venture' two majorproduct divestitures and numerous small research collaborations. While there Mr. Truex also worked with several product teams on various divestiture strategies.
Mr. Truex obtained his Masters of Business Administration in Marketing and Finance from Indiana University and a Bachelor of Arts degree in Economics from the University of Waterloo. Mr. Truex is a member of the Board of Directors of Trius Therapeutics, Eiger Biopharmaceuticals and Waterloo Pharmaceuticals, Inc.